



*JFW*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: James, Kenneth D. Ph.D., et al.

Group Art Unit: 1642

Serial Number: 10/723,933

Confirmation No. 9468

Filed: November 26, 2003

For: NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**CUSTOMER NO. 24,239**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.56 AND 37 C.F.R. § 1.97**

It is respectfully requested that the document listed on the attached Form PTO/SB/08A be considered by the Patent and Trademark Office in the above-referenced application and made of record therein. A full text copy of the relevant document is enclosed. This information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last.

Respectfully submitted,

By:

William A. Barrett  
Registration No. 42,296  
Attorney for Applicants  
Moore & Van Allen, PLLC  
2200 West Main Street, Suite 800  
Durham, NC 27705  
Phone: 919-286-8000  
Facsimile: 919-286-8199


August 20, 2004

Date

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the US Postal Service as first class mail on August 20, 2004, in an envelope addressed to Commissioner of Patents, PO Box 1450, Alexandria, VA 22313-1450

Katrina Holland



Substitute for form 1449A/PTO

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/723,933
Filing Date	November 26, 2003
First Named Inventor	James, Kenneth D. Ph.D.
Art Unit	1642
Examiner Name	
Attorney Docket Number	014811-205.108

Sheet 1 of 4

**U.S. PATENT DOCUMENTS**

Examiner Initials'	Cite No. <sup>1</sup>	Document Number		Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
	B1	US- 6,713,454		03/30/2004	Ekwuribe et al.	
	B2	US- 6,713,452		03/30/2004	Ekwuribe et al.	
	B3	US- 6,703,381		03/09/2004	Ekwuribe et al.	
	B4	US-6,638,906		10/28/2003	Ekwuribe	
	B5	US- 6,586,396		07/01/2003	Seilhamer et al.	
	B6	US- 6,583,128		06/24/2003	Ekwuribe et al.	
	B7	US- 6,541,508		04/01/2003	Ekwuribe et al.	
	B8	US- 6,309,633		10/30/2001	Ekwuribe et al.	
	B9	US- 6,191,105		02/20/2001	Ekwuribe et al.	
	B10	US- 6,117,644		09/12/2000	DeBold	
	B11	US- 6,037,145		03/14/2000	Yabuta et al.	
	B12	US- 6,028,055		02/22/2000	Lowe et al.	
	B13	US- 5,681,811		10/28/1997	Ekwuribe	
	B14	US- 5,674,710		10/07/1997	Seilhamer et al.	
	B15	US- 5,438,040		08/01/1995	Ekwuribe	
	B16	US- 5,359,030		10/25/1994	Ekwuribe	
	B17	US- 5,114,923		05/19/1992	Seilhamer et al.	
	B18	US- 5,037,741		08/06/1991	Iacobucci	
	B19	US-4,489,065		12/18/1984	Walton et al.	
	B20	US-2004/0152769		08/05/2004	Ekwuribe et al.	
	B21	US-2004/0092449		05/13/2004	Ekwuribe	
	B22	US-2004/0091452		05/13/2004	Ekwuribe et al.	
	B23	US-2004/0063630		04/01/2004	Schreiner	
	B24	US-2004/0038866		02/26/2004	Soltero et al.	
	B25	US-2004/0017387		01/29/2004	Soltero et al.	
	B26	US-2003/0229010		12/11/2003	Ekwuribe	
	B27	US-2003/0229006		12/11/2003	Ekwuribe	
	B28	US-2003/0228652		12/11/2003	Radhakrishnan et al.	
	B29	US-2003/0228275		12/11/2003	Ekwuribe et al.	
	B30	US-2003/0144468		07/31/2003	Ekwuribe et al.	
	B31	US-2003/0109420		06/12/2003	Valkirs et al.	
	B32	US-2003/0083232		05/01/2003	Soltero et al.	
	B33	US-2003/0069170		04/10/2003	Soltero et al.	
	B34	US-2003/0060606		03/27/2003	Ekwuribe et al.	
	B35	US-2003/0027995		02/06/2003	Ekwuribe et al.	
	B36	US-2003/0027748		02/06/2003	Ekwuribe et al.	
	B37	US-2003/0025559		02/06/2003	Goldenberg	
	B38	US-2003/0004304		01/02/2003	Ekwuribe et al.	

Examiner  
SignatureDate  
Considered

Substitute for form 1449A/PTO  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/723,933	
			Filing Date	November 26, 2003	
			First Named Inventor	James, Kenneth D. Ph.D.	
			Art Unit	1642	
Examiner Name					
Sheet	2	of	4	Attorney Docket Number	014811-205.108

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B39	WO 02/083913 A1	10/24/2002	Biosite Diagnostics, Inc.		
	B40	WO 01/45742	06/28/2001	Samyang Corporation		
	B41	WO 01/16295	03/08/2001	The Regents of the University of California		
	B42	WO 99/22235	05/06/1999	Shionogi & Co., Ltd.		
	B43	WO 98/45329	10/15/1998	Novo Nordisk A/S		
	B44	WO 98/17690	04/30/1998	Genentech, Inc.		
	B45	WO 98/00183 A2	01/08/1998	Shaw, Robert Francis		
	B46	WO 98/00183 A3	01/08/1998	Shaw, Robert Francis		
	B47	WO 97/34626	09/25/1997	Creative Biomolecules, Inc., et al.		
	B48	WO 95/28952	11/02/1995	Haemopep Pharma GmbH		
	B49	WO 93/24531	12/09/1993	Dzieglewska, Hanna, Eva		
	B50	WO 91/09627	07/11/1991	Hedner, Thomas, et al.		
	B51	WO 91/00292	01/10/1991	Genentech, Inc.		
	B52	EP 0 385 476 B1	07/12/1995	Daiichi Pure Chemicals Co., et al.		
	B53	EP 0 385 476 B2	09/22/1999	Shionogi & Co., Ltd.		
	B54	EP 0 418 308 B1	08/16/1999	Scios Nova Inc.		
	B55	EP 0 479 948 B1	08/26/1998	Genentech, Inc.		
	B56	EP 0 542 863 B1	11/26/1997	Scios Inc.		
	B57	EP 0 700 995 B1	03/13/1996	Suntory Limited		
	B58	EP 0 725 638 B1	08/14/1996	The University of Sheffield		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/723,933	
			Filing Date	November 26, 2003	
			First Named Inventor	James, Kenneth D. Ph.D.	
			Art Unit	1642	
			Examiner Name		
Sheet	3	of	4	Attorney Docket Number	014811-205.108

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	B59	Levin, Ellis R., et al. "Natriuretic Peptides," [Mechanisms of Disease] <i>The New England Journal of Medicine</i> , Vol. 339 No. 5, pp 321-328, July 30, 1998	
	B60	Jin, Hongkui, et al., "Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats," <i>J. clin. Invest.</i> , Vol. 98, No. 4, pp. 969-976, August 1996	
	B61	De las Fuentes, Lisa, et al., "Myocardial fatty acid metabolism independent predictor of left ventricular mass in hypertensive heart disease," <i>Hypertension</i> , pp. 83-87, January 2003	
	B62	Matsuo, Hisayuki, "Discovery of a natriuretic peptide family and their clinical application," <i>Can J. Physiol. Pharmacol.</i> 79, pp. 736-740, 2001	
	B63	Schirger, John A., et al., "Endothelin A Receptor Antagonism in Experimental Congestive Heart Failure Results in Augmentation of the Renin-Angiotensin System and Sustained Sodium Retention," <i>Circulation</i> , pp. 249-254, January 20, 2004	
	B64	Maniu, Calin V., et al., "Hemodynamic and Humoral Effects of Vasopeptidase Inhibition in Canine Hypertension," <i>Hypertension</i> , pp. 528-534, October 2002	
	B65	Chari, Y.T., et al., "Load Versus Humoral Activation in the Genesis of Early Hypertensive Heart Disease," <i>Circulation</i> , pp. 215-220, July 10, 2001	
	B66	Chen, Horng H., et al., "Endogenous Natriuretic Peptides Participate in Renal and Humoral Actions of Acute Vasopeptidase Inhibition in Experimental Mild Heart Failure," <i>Hypertension</i> , pp. 187-191, August 2001	
	B67	Cataliotti, Alessandro, et al., "Brain Natriuretic Peptide Enhances Renal Actions of Furosemide and Suppresses Furosemide-Induced Aldosterone Activation in Experimental Heart Failure," <i>Circulation</i> , pp. 1680-1685, April 6, 2004	
	B68	Boerrigter, MD, Guido, et al., "Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure," <i>Circulation</i> , pp. 686-689, February 11, 2003	
	B69	Hart, Chari Y., et al., "Differential effects of natriuretic peptides and NO on LV function in heart failure and normal dogs," <i>Am J Physiol Heart Circ. Physiol</i> , 281: H146-H154, 2001	
	B70	Lisy, MD, Ondrej, et al., "Mechanical Unloading Versus Neurohumoral Stimulation on Myocardial Structure and Endocrine Function In Vivo," <i>Circulation</i> , pp. 338-343, July 18, 2000	
	B71	Ishikawa, Hirokazu, et al., "Production of Human Calcitonin in <i>Escherichia coli</i> from Multimeric Fusion Protein," <i>Journal of Fermentation and Bioengineering</i> , Vol. 82, No. 2, pp. 140-144, 1996	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/723,933	
			Filing Date	November 26, 2003	
			First Named Inventor	James, Kenneth D. Ph.D.	
			Art Unit	1642	
			Examiner Name		
Sheet	4	of	4	Attorney Docket Number	014811-205.108

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	B72	Raingaud, J., et al., "Production, analysis and bioactivity of recombinant vasoactive intestinal peptide analogs," <i>Biochimie</i> , 78, pp. 14-25, 1996	
	B73	Lennick, Michael, et al., "High-level expression of $\alpha$ -human atrial natriuretic peptide from multiple joined genes in <i>Escherichia coli</i> ," <i>Gene</i> , 61, pp. 103-112, 1997	
	B74	Kempe, Tomas, et al., "Multiple-copy genes: production and modification of monomeric peptides from large multimeric fusion proteins," <i>Gene</i> , 39, pp. 239-245, 1985	
	B75	Wang, Jun, et al., "Overexpression and purification of recombinant atrial natriuretic peptide using hybrid fusion protein REF-ANP in <i>Escherichia coli</i> ," <i>Protein Expression and Purification</i> , 28, pp. 49-56, 2003	
	B76	Jungk, Steven John, et al., "Efficient Synthesis of C-Pivot Lariat Ethers. 2-(Alkoxymethyl)-1,4,7,10,13,16-hexaoxacyclocta-decanes," <i>J. Org. Chem</i> , 48, pp. 1116-1120, 1983	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--